Research and Practice in Thrombosis and Haemostasis最新文献_第3页

Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study 格兰兹曼血栓形成症患者的出血与生活质量--格兰兹曼 360 研究的启示

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102586

Kate Khair, Simon Fletcher, Matthew Boyton, Michael Holland

Background

Glanzmann thrombasthenia (GT) is a rare platelet function disorder that results in severe bleeding. We assessed clinical symptoms and psychological parameters to identify the unmet needs associated with GT.

Objectives

Glanzmann’s 360 is a mixed-methods study designed to give a contemporary snapshot of the impact of living with GT.

Methods

The study comprised a self-completion online survey complemented by interviews conducted with affected individuals and carers recruited via social media and hemophilia treatment centers.

Results

The survey was completed by 88 people with GT and 29 carers of children/young people with GT aged <16 years. The population ranged in age from <2 years to >70 years; 56% were female. Although 47% had been diagnosed with GT under the age of 2 years, 12% were diagnosed after 20 years of age. For 82%, a bleeding phenotype was apparent by the age of 5 years. Most respondents (88%) had experienced at least one bleed in the past week. Bleeding disproportionally affected women. Bleeds resulted in frequent hospital contact and considerable psychological distress: 26% of the population had scores suggestive of low self-esteem, while 30% met criteria suggestive of symptomatic depression. Exploratory analyses suggest that bleed experiences are associated with impaired health-related quality of life.

Conclusion

The Glanzmann’s 360 study reveals the significant physical, psychosocial, and quality-of-life impairments that are likely to be linked to the frequent bleeds experienced by those with GT. Clinicians treating people with GT should promote access to multidisciplinary comprehensive care, including psychosocial support.

背景格兰兹曼血栓形成症（GT）是一种罕见的血小板功能失调症，可导致严重出血。我们对临床症状和心理参数进行了评估，以确定与 GT 相关的未满足的需求。Glanzmann's 360 是一项混合方法研究，旨在提供有关 GT 患者生活影响的当代快照。调查对象的年龄从 2 岁到 70 岁不等；56% 为女性。47%的患者在2岁以下被诊断出患有GT，12%的患者在20岁以后才被诊断出患有GT。82%的受访者在 5 岁前就已出现出血表型。大多数受访者（88%）在过去一周内至少经历过一次出血。出血对女性的影响尤为严重。出血导致她们经常去医院就诊，并承受着巨大的心理压力：26%的人有自卑感，30%的人符合症状性抑郁的标准。探索性分析表明，出血经历与健康相关的生活质量受损有关。结论格兰兹曼 360 研究揭示了 GT 患者频繁出血可能带来的严重身体、心理和生活质量损害。治疗 GT 患者的临床医生应促进患者获得多学科综合治疗，包括心理支持。

{"title":"Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study","authors":"Kate Khair, Simon Fletcher, Matthew Boyton, Michael Holland","doi":"10.1016/j.rpth.2024.102586","DOIUrl":"10.1016/j.rpth.2024.102586","url":null,"abstract":"<div><h3>Background</h3><div>Glanzmann thrombasthenia (GT) is a rare platelet function disorder that results in severe bleeding. We assessed clinical symptoms and psychological parameters to identify the unmet needs associated with GT.</div></div><div><h3>Objectives</h3><div>Glanzmann’s 360 is a mixed-methods study designed to give a contemporary snapshot of the impact of living with GT.</div></div><div><h3>Methods</h3><div>The study comprised a self-completion online survey complemented by interviews conducted with affected individuals and carers recruited via social media and hemophilia treatment centers.</div></div><div><h3>Results</h3><div>The survey was completed by 88 people with GT and 29 carers of children/young people with GT aged <16 years. The population ranged in age from <2 years to >70 years; 56% were female. Although 47% had been diagnosed with GT under the age of 2 years, 12% were diagnosed after 20 years of age. For 82%, a bleeding phenotype was apparent by the age of 5 years. Most respondents (88%) had experienced at least one bleed in the past week. Bleeding disproportionally affected women. Bleeds resulted in frequent hospital contact and considerable psychological distress: 26% of the population had scores suggestive of low self-esteem, while 30% met criteria suggestive of symptomatic depression. Exploratory analyses suggest that bleed experiences are associated with impaired health-related quality of life.</div></div><div><h3>Conclusion</h3><div>The Glanzmann’s 360 study reveals the significant physical, psychosocial, and quality-of-life impairments that are likely to be linked to the frequent bleeds experienced by those with GT. Clinicians treating people with GT should promote access to multidisciplinary comprehensive care, including psychosocial support.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"8 7","pages":"Article 102586"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura 免疫性血栓性血小板减少性紫癜中多种抗体与 ADAMTS13 结合的机理研究

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102603

Konstantine Halkidis , Chan Meng , Vikram G. Pillai , Madison Shay , Szumam Liu , X. Long Zheng

Background

Antibody-mediated inhibition of von Willebrand factor (VWF) cleavage by ADAMTS-13 results in immune thrombotic thrombocytopenic purpura (iTTP). However, the effects of multiple antibody binding to ADAMTS-13 are not fully understood.

Objectives

To determine how multiple antibodies affect ADAMTS13 activity under various conditions.

Methods

Single-chain fragments of the variable region isolated via phage display from patients with iTTP, FRETS-VWF73, native ADAMTS-13 in normal human plasma, and hydrogen-deuterium exchange plus mass spectrometry were used.

Results

We found that 2 stimulatory antibodies affect ADAMTS-13 turnover rate more than its substrate recognition. Hydrogen-deuterium exchange plus mass spectrometry revealed that 1 of these 2 stimulatory antibodies bound to the CUB2 domain that presumably interacts with the spacer domain of ADAMTS-13. Spacer domain is targeted by most inhibitory antibodies in iTTP. Both inhibitory and stimulating antibodies could bind ADAMTS-13 simultaneously but when both were present the inhibitory activity predominates. The antibody-mediated stimulation was lost, but the inhibition persisted when a modified substrate with the amino acid residue leucine at position 1603 of VWF was replaced by an alanine (VWF73-L1603A), interfering with active site binding.

Conclusion

These results support the hypothesis that the mechanism of action of both stimulatory and inhibitory anti-ADAMTS-13 antibodies in iTTP is through allosteric modification of the catalytic domain and that inhibition of ADAMTS-13 dominates when both are present. Our findings may provide a new avenue of exploration to develop targeted diagnostic and therapeutic approaches in the management of iTTP.

背景抗体介导的 ADAMTS-13 对冯-威廉因子（VWF）裂解的抑制导致免疫性血栓性血小板减少性紫癜（iTTP）。结果我们发现两种刺激性抗体对 ADAMTS-13 转化率的影响大于对其底物识别的影响。氢氘交换和质谱分析表明，这两种刺激性抗体中的一种与CUB2结构域结合，而CUB2结构域可能与ADAMTS-13的间隔结构域相互作用。在 iTTP 中，大多数抑制性抗体都以间隔域为靶标。抑制性抗体和刺激性抗体可同时结合 ADAMTS-13，但当两者同时存在时，抑制性抗体的活性占主导地位。这些结果支持了这样的假设：在 iTTP 中，刺激性和抑制性抗 ADAMTS-13 抗体的作用机制都是通过催化结构域的异构修饰，当两者同时存在时，ADAMTS-13 的抑制作用占主导地位。我们的发现可能为开发治疗 iTTP 的靶向诊断和治疗方法提供了新的探索途径。

{"title":"Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura","authors":"Konstantine Halkidis , Chan Meng , Vikram G. Pillai , Madison Shay , Szumam Liu , X. Long Zheng","doi":"10.1016/j.rpth.2024.102603","DOIUrl":"10.1016/j.rpth.2024.102603","url":null,"abstract":"<div><h3>Background</h3><div>Antibody-mediated inhibition of von Willebrand factor (VWF) cleavage by ADAMTS-13 results in immune thrombotic thrombocytopenic purpura (iTTP). However, the effects of multiple antibody binding to ADAMTS-13 are not fully understood.</div></div><div><h3>Objectives</h3><div>To determine how multiple antibodies affect ADAMTS13 activity under various conditions.</div></div><div><h3>Methods</h3><div>Single-chain fragments of the variable region isolated via phage display from patients with iTTP, FRETS-VWF73, native ADAMTS-13 in normal human plasma, and hydrogen-deuterium exchange plus mass spectrometry were used.</div></div><div><h3>Results</h3><div>We found that 2 stimulatory antibodies affect ADAMTS-13 turnover rate more than its substrate recognition. Hydrogen-deuterium exchange plus mass spectrometry revealed that 1 of these 2 stimulatory antibodies bound to the CUB2 domain that presumably interacts with the spacer domain of ADAMTS-13. Spacer domain is targeted by most inhibitory antibodies in iTTP. Both inhibitory and stimulating antibodies could bind ADAMTS-13 simultaneously but when both were present the inhibitory activity predominates. The antibody-mediated stimulation was lost, but the inhibition persisted when a modified substrate with the amino acid residue leucine at position 1603 of VWF was replaced by an alanine (VWF73-L1603A), interfering with active site binding.</div></div><div><h3>Conclusion</h3><div>These results support the hypothesis that the mechanism of action of both stimulatory and inhibitory anti-ADAMTS-13 antibodies in iTTP is through allosteric modification of the catalytic domain and that inhibition of ADAMTS-13 dominates when both are present. Our findings may provide a new avenue of exploration to develop targeted diagnostic and therapeutic approaches in the management of iTTP.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"8 7","pages":"Article 102603"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142654129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China 70 例狼疮抗凝物-高凝血酶原血症综合征患儿的临床特征和治疗：一项来自中国单一中心的回顾性研究

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102577

Dandan Tian , Junfeng Zhang , Jintu Lou , Xuejun Chen , Juan Liang , Xiaojun Xu , Hui Gao , Wenjian Nie , Qing Ye , Hongqiang Shen

Background

Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder characterized by the presence of lupus anticoagulant (LA) and acquired hypoprothrombinemia.

Objectives

To summarize the experience of diagnosis, clinical features, and treatment of lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS).

Methods

A retrospective study of 70 children diagnosed with LAHPS from January 2019 to February 2024 at a single center was conducted.

Results

A total of 70 subjects (32 boys and 38 girls), with a mean age of 5.58 years, were included in the study. Among these subjects, 15 had autoimmune diseases (AIDs), 51 had infections, and 4 had unknown causes. Fifty-six of 70 (80%) subjects experienced bleeding with the median bleeding score of 4, 1 of 70 (1.4%) presented with thrombosis, and 13 of 70 (18.6%) were asymptomatic. All patients exhibited prolonged prothrombin time, significantly prolonged activated partial thromboplastin time, decreased factor (F)II activity (FII:C), and positive lupus anticoagulant. There was a weak negative correlation between the severity of bleeding and FII:C level (rs = −0.4283; P < .001). Patients with infection-associated LAHPS were younger than those with AIDs-associated LAHPS (P < .0001). In the study, LAHPS subjects are treated with corticosteroids as the first-line therapy, or in combination with immunosuppressants. Coagulation factor replacement therapy can effectively prevent and control bleeding events. After follow-up, lupus anticoagulant of all patients had turned negative within 12 weeks. And, prothrombin time and FII:C were completely normalized of all patients without recurrence of bleeding and without thrombosis.

Conclusion

Children develop LAHPS most commonly after AIDs and infection. Most patients presented with mild to moderate bleeding. The severity of bleeding symptoms was not exactly parallel to the decreased FII:C level.

背景狼疮抗凝物-低凝血酶原血症综合征（LAHPS）是一种罕见的获得性出血性疾病，其特征是存在狼疮抗凝物（LA）和获得性低凝血酶原血症。目的总结狼疮抗凝物-低凝血酶原血症综合征（LAHPS）的诊断、临床特征和治疗经验。方法对2019年1月至2024年2月在一个中心确诊为LAHPS的70名儿童进行回顾性研究。结果共纳入70名受试者（32名男孩和38名女孩），平均年龄为5.58岁。在这些受试者中，15 人患有自身免疫性疾病（AID），51 人患有感染，4 人病因不明。70 名受试者中有 56 人（80%）出现出血，出血中位数为 4 分，70 人中有 1 人（1.4%）出现血栓形成，70 人中有 13 人（18.6%）无症状。所有患者都表现出凝血酶原时间延长、活化部分凝血活酶时间明显延长、因子（F）II 活性（FII:C）降低和狼疮抗凝物阳性。出血严重程度与 FII:C 水平呈弱负相关（rs = -0.4283; P <.001）。感染相关 LAHPS 患者比艾滋病相关 LAHPS 患者更年轻（P < .0001）。在研究中，LAHPS 受试者接受皮质类固醇作为一线疗法，或与免疫抑制剂联合使用。凝血因子替代疗法可有效预防和控制出血事件。经过随访，所有患者的狼疮抗凝物都在 12 周内转为阴性。所有患者的凝血酶原时间和 FII:C 均完全恢复正常，未再发生出血和血栓形成。大多数患者表现为轻度至中度出血。出血症状的严重程度与 FII:C 水平的下降并不完全一致。

{"title":"Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China","authors":"Dandan Tian , Junfeng Zhang , Jintu Lou , Xuejun Chen , Juan Liang , Xiaojun Xu , Hui Gao , Wenjian Nie , Qing Ye , Hongqiang Shen","doi":"10.1016/j.rpth.2024.102577","DOIUrl":"10.1016/j.rpth.2024.102577","url":null,"abstract":"<div><h3>Background</h3><div>Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder characterized by the presence of lupus anticoagulant (LA) and acquired hypoprothrombinemia.</div></div><div><h3>Objectives</h3><div>To summarize the experience of diagnosis, clinical features, and treatment of lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS).</div></div><div><h3>Methods</h3><div>A retrospective study of 70 children diagnosed with LAHPS from January 2019 to February 2024 at a single center was conducted.</div></div><div><h3>Results</h3><div>A total of 70 subjects (32 boys and 38 girls), with a mean age of 5.58 years, were included in the study. Among these subjects, 15 had autoimmune diseases (AIDs), 51 had infections, and 4 had unknown causes. Fifty-six of 70 (80%) subjects experienced bleeding with the median bleeding score of 4, 1 of 70 (1.4%) presented with thrombosis, and 13 of 70 (18.6%) were asymptomatic. All patients exhibited prolonged prothrombin time, significantly prolonged activated partial thromboplastin time, decreased factor (F)II activity (FII:C), and positive lupus anticoagulant. There was a weak negative correlation between the severity of bleeding and FII:C level (<em>rs</em> = −0.4283; <em>P</em> < .001). Patients with infection-associated LAHPS were younger than those with AIDs-associated LAHPS (<em>P</em> < .0001). In the study, LAHPS subjects are treated with corticosteroids as the first-line therapy, or in combination with immunosuppressants. Coagulation factor replacement therapy can effectively prevent and control bleeding events. After follow-up, lupus anticoagulant of all patients had turned negative within 12 weeks. And, prothrombin time and FII:C were completely normalized of all patients without recurrence of bleeding and without thrombosis.</div></div><div><h3>Conclusion</h3><div>Children develop LAHPS most commonly after AIDs and infection. Most patients presented with mild to moderate bleeding. The severity of bleeding symptoms was not exactly parallel to the decreased FII:C level.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"8 7","pages":"Article 102577"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of the VTE-PREDICT calculator on clinicians’ decision making in fictional patients with venous thromboembolism: a randomized controlled trial VTE-PREDICT 计算器对临床医生为静脉血栓栓塞症虚构患者做出决策的影响：随机对照试验

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102569

Daniël Duijzer , Maria A. de Winter , Marc Carrier , Alexander T. Cohen , John-Bjarne Hansen , Karin A.H. Kaasjager , Ajay K. Kakkar , Saskia Middeldorp , Henrik T. Sørensen , Frank L.J. Visseren , Philip S. Wells , Jannick A.N. Dorresteijn , Mathilde Nijkeuter

Background

After 3 months of anticoagulation for venous thromboembolism (VTE), the decision needs to be made whether to stop anticoagulation or extend treatment indefinitely. The VTE-PREDICT calculator can be used to estimate individual risks of VTE recurrence and bleeding to guide this decision.

Objectives

To evaluate the impact of predicted individual risks of recurrence and bleeding on clinicians’ decisions on anticoagulation duration and to assess usefulness of the VTE-PREDICT calculator.

Methods

A randomized controlled trial and within-subject study was conducted among clinicians treating VTE patients. The clinicians were asked to complete an online survey containing 6 fictional case vignettes. Group A proposed anticoagulant duration for each case without additional information first and subsequently after seeing calculator-predicted risks (within-subject analysis). Group B was directly provided with calculator risks and proposed treatment duration for each case vignette (for comparison with group A results in a randomized controlled trial analysis). Then, group B received questions on usefulness and credibility of the calculator.

Results

Forty-five clinicians were assigned to group A and 48 to B. Overall, group A did not propose different anticoagulation durations than group B. However, individual clinicians in group A changed proposed duration in 35% of the cases after seeing the calculator risks. The calculator was considered useful and credible by most clinicians.

Conclusion

Overall, use of the VTE-PREDICT calculator did not affect proposed anticoagulation duration. However, individual clinicians frequently changed their proposed duration after using the calculator, especially for patients with high bleeding risk.

背景静脉血栓栓塞症（VTE）抗凝治疗 3 个月后，需要决定是停止抗凝还是无限期延长治疗。VTE-PREDICT 计算器可用于估算 VTE 复发和出血的个体风险，从而为这一决策提供指导。方法在治疗 VTE 患者的临床医生中开展了一项随机对照试验和受试者内研究。临床医生被要求完成一份包含 6 个虚构病例的在线调查。A 组首先在没有额外信息的情况下提出每个病例的抗凝时间，随后在看到计算器预测的风险后提出抗凝时间（受试者内分析）。B 组直接获得计算器预测的风险和每个病例小故事的建议治疗时间（用于在随机对照试验分析中与 A 组的结果进行比较）。结果45 名临床医生被分配到 A 组，48 名被分配到 B 组。总体而言，A 组提出的抗凝治疗持续时间与 B 组相比并无不同。然而，A 组的个别临床医生在看到计算器风险后改变了 35% 的病例的建议持续时间。大多数临床医生认为计算器有用且可信。然而，个别临床医生在使用计算器后经常会改变其建议的持续时间，尤其是对出血风险较高的患者。

{"title":"Impact of the VTE-PREDICT calculator on clinicians’ decision making in fictional patients with venous thromboembolism: a randomized controlled trial","authors":"Daniël Duijzer , Maria A. de Winter , Marc Carrier , Alexander T. Cohen , John-Bjarne Hansen , Karin A.H. Kaasjager , Ajay K. Kakkar , Saskia Middeldorp , Henrik T. Sørensen , Frank L.J. Visseren , Philip S. Wells , Jannick A.N. Dorresteijn , Mathilde Nijkeuter","doi":"10.1016/j.rpth.2024.102569","DOIUrl":"10.1016/j.rpth.2024.102569","url":null,"abstract":"<div><h3>Background</h3><div>After 3 months of anticoagulation for venous thromboembolism (VTE), the decision needs to be made whether to stop anticoagulation or extend treatment indefinitely. The VTE-PREDICT calculator can be used to estimate individual risks of VTE recurrence and bleeding to guide this decision.</div></div><div><h3>Objectives</h3><div>To evaluate the impact of predicted individual risks of recurrence and bleeding on clinicians’ decisions on anticoagulation duration and to assess usefulness of the VTE-PREDICT calculator.</div></div><div><h3>Methods</h3><div>A randomized controlled trial and within-subject study was conducted among clinicians treating VTE patients. The clinicians were asked to complete an online survey containing 6 fictional case vignettes. Group A proposed anticoagulant duration for each case without additional information first and subsequently after seeing calculator-predicted risks (within-subject analysis). Group B was directly provided with calculator risks and proposed treatment duration for each case vignette (for comparison with group A results in a randomized controlled trial analysis). Then, group B received questions on usefulness and credibility of the calculator.</div></div><div><h3>Results</h3><div>Forty-five clinicians were assigned to group A and 48 to B. Overall, group A did not propose different anticoagulation durations than group B. However, individual clinicians in group A changed proposed duration in 35% of the cases after seeing the calculator risks. The calculator was considered useful and credible by most clinicians.</div></div><div><h3>Conclusion</h3><div>Overall, use of the VTE-PREDICT calculator did not affect proposed anticoagulation duration. However, individual clinicians frequently changed their proposed duration after using the calculator, especially for patients with high bleeding risk.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"8 7","pages":"Article 102569"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to treat patients with bleeding disorder of unknown cause? 如何治疗原因不明的出血性疾病患者？

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102585

Caroline Mussert , Amaury Monard , Floor Heubel-Moenen

引用次数: 0

Balancing safety and efficacy of low-molecular-weight heparins in neonates: a systematic review 平衡新生儿使用低分子量肝素的安全性和有效性：系统综述

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102601

Marieke Verweij , Mirjam M. van Weissenbruch , Irene L.M. Klaassen

The rising incidence of venous thromboembolism (VTE) in neonates has led to increased use of low-molecular-weight heparins (LMWHs), but optimal dosages remain uncertain. A serious adverse effect of LMWHs is major bleeding. Given the vulnerability of neonates to major bleeding, we aimed to review therapeutic and prophylactic LMWH dosages to achieve target anti-factor Xa ranges of 0.5 and 1.0 U/mL and 0.1 and 0.4 U/mL, respectively. Our secondary aim was to assess the safety and efficacy of LMWHs in neonates. A systematic review of all published studies between 1996 and 2023 that pertained to the dosing, safety, or efficacy of LMWH in preterm and term neonates. Studies were identified through the Medline database. Data on LMWH dosages, bleeding events, resolution and recurrence, and anti-factor Xa levels were analyzed. A total of 38 studies involving 1145 neonates were included. To achieve a therapeutic or prophylactic target range, weight-adjusted initial dosages of LMWH had to be increased by 21% particularly in premature neonates. During therapeutic therapy, major bleeding occurred in 4.1% and minor bleeding in 7.1%. During prophylactic therapy, 11.4% experienced major bleeding and 17.1% minor bleeding. With therapeutic dosages, 55.8% achieved complete VTE resolution. Additionally, 68.5% of neonates initially failed to achieve therapeutic anti-factor Xa levels, persisting in 29.4% despite dose adjustments. A higher initial therapeutic dosage of LMWHs may be needed in neonates. In addition, the patient’s gestational age must be considered in the dosing strategy to optimize outcomes. Although this must be weighed against bleeding risk at an individual level.

新生儿静脉血栓栓塞症（VTE）的发病率不断上升，导致低分子量肝素（LMWHs）的使用增加，但最佳剂量仍不确定。LMWHs 的一个严重不良反应是大出血。鉴于新生儿易发生大出血，我们旨在审查治疗性和预防性 LMWH 剂量，以实现抗因子 Xa 的目标范围分别为 0.5 和 1.0 U/mL，以及 0.1 和 0.4 U/mL。我们的次要目的是评估 LMWHs 在新生儿中的安全性和有效性。我们对 1996 年至 2023 年间发表的所有有关早产儿和足月新生儿 LMWH 剂量、安全性或疗效的研究进行了系统性回顾。研究通过 Medline 数据库进行鉴定。分析了有关 LMWH 剂量、出血事件、缓解和复发以及抗因子 Xa 水平的数据。共纳入了 38 项研究，涉及 1145 名新生儿。为达到治疗或预防目标范围，经体重调整后的 LMWH 初始剂量必须增加 21%，尤其是早产新生儿。在治疗过程中，4.1%的新生儿出现大出血，7.1%的新生儿出现轻微出血。在预防性治疗期间，11.4%的新生儿出现大出血，17.1%出现轻微出血。在治疗剂量下，55.8% 的新生儿完全消除了 VTE。此外，68.5% 的新生儿最初未能达到治疗性抗因子 Xa 水平，29.4% 的新生儿在调整剂量后仍未能达到治疗性抗因子 Xa 水平。新生儿可能需要更高的 LMWHs 初始治疗剂量。此外，在剂量策略中还必须考虑患者的妊娠年龄，以优化治疗效果。尽管这必须根据个体情况与出血风险进行权衡。

{"title":"Balancing safety and efficacy of low-molecular-weight heparins in neonates: a systematic review","authors":"Marieke Verweij , Mirjam M. van Weissenbruch , Irene L.M. Klaassen","doi":"10.1016/j.rpth.2024.102601","DOIUrl":"10.1016/j.rpth.2024.102601","url":null,"abstract":"<div><div>The rising incidence of venous thromboembolism (VTE) in neonates has led to increased use of low-molecular-weight heparins (LMWHs), but optimal dosages remain uncertain. A serious adverse effect of LMWHs is major bleeding. Given the vulnerability of neonates to major bleeding, we aimed to review therapeutic and prophylactic LMWH dosages to achieve target anti-factor Xa ranges of 0.5 and 1.0 U/mL and 0.1 and 0.4 U/mL, respectively. Our secondary aim was to assess the safety and efficacy of LMWHs in neonates. A systematic review of all published studies between 1996 and 2023 that pertained to the dosing, safety, or efficacy of LMWH in preterm and term neonates. Studies were identified through the Medline database. Data on LMWH dosages, bleeding events, resolution and recurrence, and anti-factor Xa levels were analyzed. A total of 38 studies involving 1145 neonates were included. To achieve a therapeutic or prophylactic target range, weight-adjusted initial dosages of LMWH had to be increased by 21% particularly in premature neonates. During therapeutic therapy, major bleeding occurred in 4.1% and minor bleeding in 7.1%. During prophylactic therapy, 11.4% experienced major bleeding and 17.1% minor bleeding. With therapeutic dosages, 55.8% achieved complete VTE resolution. Additionally, 68.5% of neonates initially failed to achieve therapeutic anti-factor Xa levels, persisting in 29.4% despite dose adjustments. A higher initial therapeutic dosage of LMWHs may be needed in neonates. In addition, the patient’s gestational age must be considered in the dosing strategy to optimize outcomes. Although this must be weighed against bleeding risk at an individual level.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"8 7","pages":"Article 102601"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to ‘Hand grip strength and risk of incident venous thromboembolism: The Tromsø study’ 手部握力与静脉血栓栓塞症发病风险：特罗姆瑟研究

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102621

Oda G.R. Leknessund BSc , Vania M. Morelli MD PhD , Bjørn Heine Strand , John-Bjarne Hansen MD PhD , Sigrid K. Brækkan PhD

引用次数: 0

Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores 多发性骨髓瘤：常规血栓预防措施和血栓风险评分效用的回顾性评估

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102571

Omar Eduardo Fernandez-Vargas, Isabel Amezcua, Beatriz Cabello, Andrea Quintana Martinez, Ramiro Espinoza, Gabriela Cesarman-Maus

Background

The high risk of venous thromboembolism (VTE) in multiple myeloma (MM) warrants primary thromboprophylaxis for most patients. Myeloma-specific thrombotic risk scores (TRSs), such as IMPEDE-VTE, SAVED, and PRISM, were developed to improve risk assessment and guide antithrombotic strategies. Their performance is variable and has not yet been tested in Latin America.

Objectives

We aimed to assess the use of primary thromboprophylaxis, the incidence of VTE and bleeding events, and the effectiveness of TRSs in patients with newly diagnosed MM.

Methods

This was a retrospective, single-center study. Cumulative VTE rates and TRS performance were analyzed using survival and receiver operating characteristic curves.

Results

The study included 250 newly diagnosed MM patients; the vast majority (98.6%) received aspirin as thromboprophylaxis. VTE occurred in 8% within the initial 6 months, increasing to 14.8% over a median follow-up of 19 months. High rates of major bleeding (4.8%) and clinically relevant nonmajor bleeding (4.4%) events were documented. A minimal proportion (0.8%, 0.5%, and 1.2%) of patients were classified as low risk by IMPEDE-VTE, PRISM, and SAVED scores, respectively. Only IMPEDE-VTE exhibited a trend for distinguishing between intermediate-risk (7.14%) and high-risk (13.2%) groups (P = .09). PRISM and SAVED scores showed limited utility. VTE did not impact survival.

Conclusion

Aspirin as primary thromboprophylaxis carries an unacceptable risk of VTE and bleeding in patients at intermediate or high thrombotic risk. The IMPEDE-VTE score performed best, although without reaching statistical significance. We confirm that VTE does not portend poor overall survival in MM.

背景多发性骨髓瘤（MM）患者发生静脉血栓栓塞（VTE）的风险很高，因此大多数患者都需要进行初级血栓预防。骨髓瘤特异性血栓风险评分（TRS），如IMPEDE-VTE、SAVED和PRISM，是为改善风险评估和指导抗血栓策略而开发的。我们旨在评估新诊断出的 MM 患者中初级血栓预防措施的使用情况、VTE 和出血事件的发生率以及 TRS 的有效性。结果该研究纳入了250名新诊断的MM患者，其中绝大多数（98.6%）接受了阿司匹林作为血栓预防药物。最初 6 个月内发生 VTE 的比例为 8%，中位随访 19 个月后增加到 14.8%。大出血（4.8%）和临床相关的非大出血（4.4%）事件的发生率很高。根据 IMPEDE-VTE、PRISM 和 SAVED 评分，被归类为低风险的患者比例极低（分别为 0.8%、0.5% 和 1.2%）。只有 IMPEDE-VTE 有区分中危（7.14%）和高危（13.2%）组的趋势（P = .09）。PRISM 和 SAVED 评分的作用有限。结论阿司匹林作为主要血栓预防药物，对中度或高度血栓风险患者而言，具有不可接受的 VTE 和出血风险。IMPEDE-VTE评分表现最佳，但未达到统计学意义。我们证实，VTE 并不预示着 MM 患者的总生存率较低。

{"title":"Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores","authors":"Omar Eduardo Fernandez-Vargas, Isabel Amezcua, Beatriz Cabello, Andrea Quintana Martinez, Ramiro Espinoza, Gabriela Cesarman-Maus","doi":"10.1016/j.rpth.2024.102571","DOIUrl":"10.1016/j.rpth.2024.102571","url":null,"abstract":"<div><h3>Background</h3><div>The high risk of venous thromboembolism (VTE) in multiple myeloma (MM) warrants primary thromboprophylaxis for most patients. Myeloma-specific thrombotic risk scores (TRSs), such as IMPEDE-VTE, SAVED, and PRISM, were developed to improve risk assessment and guide antithrombotic strategies. Their performance is variable and has not yet been tested in Latin America.</div></div><div><h3>Objectives</h3><div>We aimed to assess the use of primary thromboprophylaxis, the incidence of VTE and bleeding events, and the effectiveness of TRSs in patients with newly diagnosed MM.</div></div><div><h3>Methods</h3><div>This was a retrospective, single-center study. Cumulative VTE rates and TRS performance were analyzed using survival and receiver operating characteristic curves.</div></div><div><h3>Results</h3><div>The study included 250 newly diagnosed MM patients; the vast majority (98.6%) received aspirin as thromboprophylaxis. VTE occurred in 8% within the initial 6 months, increasing to 14.8% over a median follow-up of 19 months. High rates of major bleeding (4.8%) and clinically relevant nonmajor bleeding (4.4%) events were documented. A minimal proportion (0.8%, 0.5%, and 1.2%) of patients were classified as low risk by IMPEDE-VTE, PRISM, and SAVED scores, respectively. Only IMPEDE-VTE exhibited a trend for distinguishing between intermediate-risk (7.14%) and high-risk (13.2%) groups (<em>P</em> = .09). PRISM and SAVED scores showed limited utility. VTE did not impact survival.</div></div><div><h3>Conclusion</h3><div>Aspirin as primary thromboprophylaxis carries an unacceptable risk of VTE and bleeding in patients at intermediate or high thrombotic risk. The IMPEDE-VTE score performed best, although without reaching statistical significance. We confirm that VTE does not portend poor overall survival in MM.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"8 7","pages":"Article 102571"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hyperfibrinolysis: a crucial phenotypic abnormality of posttraumatic fibrinolytic dysfunction 纤溶亢进：创伤后纤溶功能障碍的关键表型异常

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102568

Kyosuke Takahashi , Kazuma Yamakawa , Anaar E. Siletz , Morihiro Katsura , John B. Holcomb , Charles E. Wade , Jessica C. Cardenas , Erin E. Fox , Morgan Schellenberg , Matthew Martin , Kenji Inaba , Kazuhide Matsushima

Background

Traumatic fibrinolytic dysfunction is often categorized into 3 phenotypes based on the result of thromboelastography (TEG) lysis at 30 minutes (LY30): fibrinolysis shutdown, physiologic fibrinolysis, and hyperfibrinolysis. However, the molecular pathophysiology of fibrinolytic dysfunction and the association with clinical outcomes have not been fully evaluated.

Objectives

To assess whether posttraumatic fibrinolysis phenotypes identified by TEG correlate with levels of key fibrinolysis-related serum markers and with risk of mortality and hospital complications.

Methods

This is a secondary analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial. Patients were stratified according to the degree of fibrinolysis upon arrival using TEG LY30 values: low LY30, <0.8%; normal LY30, 0.81% to 0.9%; and high LY30, ≥3%. Serial values of molecular markers (0-72 hours after admission) and clinical outcomes were compared between fibrinolysis groups.

Results

A total of 547 patients were included (low LY30, 320; normal LY30, 108; high LY30, 119). The high LY30 group had higher tissue plasminogen activator and plasmin-antiplasmin values upon hospital arrival than the low LY30 or normal LY30 groups (P < .001, respectively). There was no significant difference in levels of tissue plasminogen activator, plasmin-antiplasmin, and plasminogen activator inhibitor 1 between the low LY30 and normal LY30 groups. The high LY30 group was associated with an increased risk of 24-hour and 30-day mortality, while there was no significant difference in mortality between the low LY30 and normal LY30 groups.

Conclusion

Our results suggest that hyperfibrinolysis is the most common form of traumatic fibrinolytic dysfunction and is associated with worse outcome.

背景创伤性纤溶功能障碍通常根据血栓弹性成像（TEG）30 分钟裂解（LY30）的结果分为 3 种表型：纤溶关闭、生理性纤溶和纤溶亢进。目标评估 TEG 确定的创伤后纤维蛋白溶解表型是否与关键纤维蛋白溶解相关血清标志物水平以及死亡率和住院并发症风险相关。方法这是一项实用随机优化血小板和血浆比例试验的二次分析。根据患者到达时的纤溶程度，使用 TEG LY30 值对患者进行分层：低 LY30，0.8%；正常 LY30，0.81% 至 0.9%；高 LY30，≥3%。结果共纳入 547 例患者（低 LY30，320 例；正常 LY30，108 例；高 LY30，119 例）。与低 LY30 组或正常 LY30 组相比，高 LY30 组患者入院时的组织纤溶酶原激活剂和纤溶酶-抗凝血酶值更高（分别为 P < .001）。低 LY30 组和正常 LY30 组的组织纤溶酶原激活因子、纤溶酶-抗纤溶酶原和纤溶酶原激活因子抑制剂 1 的水平没有明显差异。结论我们的研究结果表明，纤溶亢进是创伤性纤溶功能障碍最常见的形式，与较差的预后有关。

{"title":"Hyperfibrinolysis: a crucial phenotypic abnormality of posttraumatic fibrinolytic dysfunction","authors":"Kyosuke Takahashi , Kazuma Yamakawa , Anaar E. Siletz , Morihiro Katsura , John B. Holcomb , Charles E. Wade , Jessica C. Cardenas , Erin E. Fox , Morgan Schellenberg , Matthew Martin , Kenji Inaba , Kazuhide Matsushima","doi":"10.1016/j.rpth.2024.102568","DOIUrl":"10.1016/j.rpth.2024.102568","url":null,"abstract":"<div><h3>Background</h3><div>Traumatic fibrinolytic dysfunction is often categorized into 3 phenotypes based on the result of thromboelastography (TEG) lysis at 30 minutes (LY30): fibrinolysis shutdown, physiologic fibrinolysis, and hyperfibrinolysis. However, the molecular pathophysiology of fibrinolytic dysfunction and the association with clinical outcomes have not been fully evaluated.</div></div><div><h3>Objectives</h3><div>To assess whether posttraumatic fibrinolysis phenotypes identified by TEG correlate with levels of key fibrinolysis-related serum markers and with risk of mortality and hospital complications.</div></div><div><h3>Methods</h3><div>This is a secondary analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial. Patients were stratified according to the degree of fibrinolysis upon arrival using TEG LY30 values: low LY30, <0.8%; normal LY30, 0.81% to 0.9%; and high LY30, ≥3%. Serial values of molecular markers (0-72 hours after admission) and clinical outcomes were compared between fibrinolysis groups.</div></div><div><h3>Results</h3><div>A total of 547 patients were included (low LY30, 320; normal LY30, 108; high LY30, 119). The high LY30 group had higher tissue plasminogen activator and plasmin-antiplasmin values upon hospital arrival than the low LY30 or normal LY30 groups (<em>P</em> < .001, respectively). There was no significant difference in levels of tissue plasminogen activator, plasmin-antiplasmin, and plasminogen activator inhibitor 1 between the low LY30 and normal LY30 groups. The high LY30 group was associated with an increased risk of 24-hour and 30-day mortality, while there was no significant difference in mortality between the low LY30 and normal LY30 groups.</div></div><div><h3>Conclusion</h3><div>Our results suggest that hyperfibrinolysis is the most common form of traumatic fibrinolytic dysfunction and is associated with worse outcome.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"8 7","pages":"Article 102568"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142419946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparable hemostatic capacity of blood taken from the portal vein compared with systemic blood in patients with cirrhosis 肝硬化患者门静脉血液与全身血液的止血能力相当

IF 3.4 3区医学 Q2 HEMATOLOGY

Research and Practice in Thrombosis and Haemostasis

Pub Date : 2024-10-01 DOI: 10.1016/j.rpth.2024.102583

Annabel Blasi , Andrea Calvo , Ricard Mellado , Miguel Angel Torrente , Fanny Turon , Juan Carlos Garcia-Pagan , Virginia Hernandez-Gea , Dolors Tassies , Joan Carles Reverter , Ton Lisman

引用次数: 0